# EDGAR Filing Document

**Accession Number:** 0001382574
**File Stem:** 0001641172-25-019549
**Filing Date:** 2025-7
**Character Count:** 2993
**Document Hash:** d653e12b75c6fc727e0218febe5ceecf
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-019549.hdr.sgml**: 20250715

**ACCESSION NUMBER**: 0001641172-25-019549

**CONFORMED SUBMISSION TYPE**: 1-A-W

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250715

**DATE AS OF CHANGE**: 20250714

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Scienture Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001382574
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 1-A-W
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12510
- **FILM NUMBER:** 251122616

**BUSINESS ADDRESS:**
- **STREET 1:** 20 AUSTIN BLVD.
- **CITY:** COMMACK
- **STATE:** NY
- **ZIP:** 11725
- **BUSINESS PHONE:** (800) 261 0281

**MAIL ADDRESS:**
- **STREET 1:** 20 AUSTIN BLVD.
- **CITY:** COMMACK
- **STATE:** NY
- **ZIP:** 11725

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRxADE HEALTH, INC
- **DATE OF NAME CHANGE:** 20210602

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TRXADE GROUP, INC.
- **DATE OF NAME CHANGE:** 20140207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** XCELLINK INTERNATIONAL INC.
- **DATE OF NAME CHANGE:** 20081230

![](form1-aw_001.jpg)

July 14, 2025

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Scienture Holdings, Inc.**<br> **Withdrawal of Offering Statement on Form 1-A, filed September 25, 2024**<br> **File No. 024-12510**<br>|

---

Ladies and Gentlemen:

Pursuant to Rule 259(a) under Regulation A of the Securities Act of 1933, as amended, the Company hereby respectfully requests the withdrawal of the above-referenced Offering Statement, together with all exhibits thereto (collectively, the "Offering Statement"), originally filed with the Securities and Exchange Commission (the "Commission") via EDGAR on September 25, 2024.

The Company is requesting to withdraw the Offering Statement as the Company has decided it is not in the best interests of the Company or its shareholders to continue with the proposed offering described in the Offering Statement at this time.

The Offering Statement has not been qualified by the Commission and no offering or sale of the securities that are the subject of the Offering Statement were made. Accordingly, the Company respectfully requests that the Commission issue an order granting the withdrawal of the Offering Statement effective as of the date hereof or at the earliest practicable date hereafter.

Should you have any questions regarding these matters, please contact our counsel, Kate Bechen, of Dykema Gossett PLLC at kbechen@dykema.com.

---

| | |
|:---|:---|
| Sincerely, | Sincerely, |
| By: | */s/ Narasimhan Mani* |
| Name: | Narasimhan Mani |
| Title: | Co-Chief Executive Officer and President |

---

cc: Kate Bechen, Esq.